Novartis (NOVN.S) said on Monday it agreed to acquire Seattle-based biotech firm Chinook Therapeutics (KDNY.O) for up to $3.5 billion to boost its late-stage drug development line-up with a new treatment for a rare severe kidney disease.
The transaction, in the form of a merger of a newly formed Novartis subsidiary and Chinook, is expected to close in the second half of 2023, the Swiss drugmaker said in a statement.
Under the agreed deal, Chinook shareholders would receive $3.2 billion, or $40 per share, in cash plus a contingent value right worth up to $300 million, depending on certain regulatory achievements, it said.
Chinook shares closed at $23.99 on Friday.
The U.S. biotech firm expects to see the pivotal readout in the fourth quarter of this year of a clinical trial in the third and last stage of development of oral drug candidate atrasentan to treat a kidney disease known as IgAN.
Chinook also has zigakibart, another experimental IgAN treatment, under development and plans to start a Phase 3 in the third quarter of 2023.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
